Xcout Intel
Great Bay Bio competitors & alternatives
The 12 closest competitors and alternatives to Great Bay Bio among biotechnology companies — ranked by similarity to what Great Bay Bio actually does, not by market-cap band.
Subscribe to see Great Bay Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Great Bay Bio
Great Bay Bio is a biotech company headquartered in HKSTP that drives drug development using cutting-edge technologies such as AI and big data mining.
Great Bay Bio at a glance
Great Bay Bio is a biotechnology company headquartered in China. It has raised at least $25M across the 2 funding rounds on record. Its most recent funding round raised $15M in September 2022. Xcout tracks 4 named people at Great Bay Bio, including Michael Chen (Co-founder & CEO).
Great Bay Bio leadership
- Michael ChenCo-founder & CEO
- Kingsley LeungCo-founder & Chairman
- Chibo TangManaging Partner of Gobi
- George LiManaging Partner of Proxima Ventures
Great Bay Bio funding rounds
At least $25M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $15M | 1 named | |
| Series A | $10M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Great Bay Bio competitors
Ranked by semantic similarity — how close each company is to Great Bay Bio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.
Similar biotechnology company
Avicenna Biosciences, Inc. is a biotechnology company that uses machine learning-enhanced medicinal chemistry to accelerate drug discovery and optimization.
Similar biotechnology company
Noetik Inc. is an AI-native biotechnology company headquartered in South San Francisco, California, leveraging advanced machine learning methods for biological discovery.
Biotech
Healx is an AI-native pharmaceutical company that uses artificial intelligence and technology to discover and develop new treatments for rare diseases. The company redevelops, combines, and enhances known compounds to build a drug pipeline aimed at delivering effective therapies to patients.
Similar biotechnology company
9Bio Therapeutics is a biotechnology company that combines biology, structural engineering, and artificial intelligence to pioneer next-generation biologics for advanced cancers. The company is headquartered in Quebec, Canada.
Similar biotechnology company
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Biotech
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Biotech
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Biotech
Harmonic Discovery is a drug discovery company founded in 2021 and headquartered in New York City. The company leverages machine learning and precision pharmacology to develop therapeutics for complex diseases.
Biotech
1910 Genetics is a biotechnology company that integrates artificial intelligence with biology to accelerate drug discovery. Their mission is to reduce the timeline and cost of developing treatments for genetic diseases.
Biotech
XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensive drug discovery services encompass the entire research and development process, ranging from target validation and hit identification to lead generation, lead optimization, and PCC nomination. These services are adept across diverse therapeutic modalities, such as small molecules, antibodies, peptides, ADCs, and PROTACs. The company's intelligent automation solutions specifically utilize artificial intelligence and automation to facilitate the accelerated discovery and research of novel drugs and materials. Established in 2015 and based in Shenzhen, China, the firm was formerly known as QuantumPharm Inc. before officially changing its name to XtalPi Holdings Limited in December 2024.
Similar biotechnology company
Superluminal Medicines is a generative biology and chemistry company headquartered in Boston, Massachusetts, focused on drug discovery and development.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Great Bay Bio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Great Bay Bioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →